Enrique Grande: EVITA Criteria for Ineligibility in EV/Pembro for Metastatic Urothelial Cancer
Oct 31, 2024, 15:47

Enrique Grande: EVITA Criteria for Ineligibility in EV/Pembro for Metastatic Urothelial Cancer

Enrique Grande, Head of Oncology at MD Anderson Cancer Center Madrid, shared on LinkedIn:

” EVITA (EV Ineligible criTeriA) criteria for identifying patients ineligible for the EV/Pembro combo in metastatic urothelial carcinoma.

Re: Thomas Powles, Begoña Pérez-Valderrama, Shilpa Gupta, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.

Authors: Enrique Grande, Alison Jane Birtle, Ashish M. Kamat.

Enrique Grande: EVITA Criteria for Ineligibility in EV/Pembro for Metastatic Urothelial Cancer

Enrique Grande, MD, PhD, MSc, is an Associate Professor at Francisco de Vitoria University. He is also an Adjunct Professor at the GU Medical Oncology Department and the Head of Oncology at MD Anderson Cancer Center. Grande specializes in researching genitourinary and endocrine tumors and actively collaborates in developing the Translational Research and Early Drug Development Unit. He founded the Spanish Group for Research on Orphan and Uncommon Tumors (GETHI) and serves on the Directory Board of the Spanish Task Force Group for NETs (GETNE). Dr. Grande edits several international journals and has participated in recent neuroendocrine tumor trials that led to the approval of new drugs in this field.